Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.
about
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Secukinumab in Active Rheumato ...... cebo-Controlled Phase 3 Study.
@en
Secukinumab in Active Rheumato ...... cebo-Controlled Phase 3 Study.
@nl
type
label
Secukinumab in Active Rheumato ...... cebo-Controlled Phase 3 Study.
@en
Secukinumab in Active Rheumato ...... cebo-Controlled Phase 3 Study.
@nl
prefLabel
Secukinumab in Active Rheumato ...... cebo-Controlled Phase 3 Study.
@en
Secukinumab in Active Rheumato ...... cebo-Controlled Phase 3 Study.
@nl
P2093
P2860
P1476
Secukinumab in Active Rheumato ...... cebo-Controlled Phase 3 Study.
@en
P2093
Atul Deodhar
Filip Van den Bosch
Hanno B Richards
Jacob Aelion
Mark Genovese
Sibylle Haemmerle
Tsutomu Takeuchi
P2860
P2888
P304
P356
10.1007/S40744-017-0086-Y
P50
P577
2017-11-14T00:00:00Z